21 research outputs found
Differential diagnosis of traumatic brain injury
Objective: Π’ΠΎ search for the most difficult areas of the differential diagnosis of TBI, the definition of statistically significant differential diagnosis criteria for designated areas - the first stage of the development of decision support systems of medical solutions in this area. Materials and Methods: The study consisted of several stages. In the first stage was retrospectively analyzed 2,156 cases of moderate and severe traumatic brain injury complicated directions to find the differential diagnosis of traumatic brain injury. In the second stage search criteria performed differential diagnosis of brain injuries in the directions indicated by the first stage. Criteria marked with a solid analysis of 726 prospective cases that were 6 groups of comparison. Results: were identified statistically valid differential diagnostic criteria for each of the most difficult areas identified in the first stage. Signs formed from the most simple study of clinical and instrumental tests. Conclusion: The clinical and statistical principle of formation of differential criteria on the most important areas of the differential diagnosis of TBI, allowed to identify statistically significant criteria that can be used as the basis for the creation of funds to support medical decision-making.Π¦Π΅Π»Ρ: ΠΏΠΎΠΈΡΠΊ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ»ΠΎΠΆΠ½ΡΡ
Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΉ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π§ΠΠ’, ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΏΠΎ ΠΎΠ±ΠΎΠ·Π½Π°ΡΠ΅Π½Π½ΡΠΌ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡΠΌ - ΠΊΠ°ΠΊ ΠΏΠ΅ΡΠ²ΡΠΉ ΡΡΠ°ΠΏ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΠΈΡΡΠ΅ΠΌΡ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠΈ ΠΏΡΠΈΠ½ΡΡΠΈΡ Π²ΡΠ°ΡΠ΅Π±Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΏΠΎ Π΄Π°Π½Π½ΠΎΠΌΡ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΡΠ°Π±ΠΎΡΠ° ΡΠΎΡΡΠΎΡΠ»Π° ΠΈΠ· Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΡ
ΡΡΠ°ΠΏΠΎΠ². ΠΠ° ΠΏΠ΅ΡΠ²ΠΎΠΌ ΡΡΠ°ΠΏΠ΅ Π±ΡΠ»ΠΎ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½ΠΎ 2156 ΡΠ»ΡΡΠ°Π΅Π² ΡΡΠ΅Π΄Π½Π΅ΠΉ ΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΠ΅ΡΠ΅ΠΏΠ½ΠΎΒΠΌΠΎΠ·Π³ΠΎΠ²ΠΎΠΉ ΡΡΠ°Π²ΠΌΡ Π΄Π»Ρ ΠΏΠΎΠΈΡΠΊΠ° Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΉ ΡΠ»ΠΎΠΆΠ½ΠΎΠΉ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΠ΅ΡΠ΅ΠΏΠ½ΠΎ-ΠΌΠΎΠ·Π³ΠΎΠ²ΠΎΠΉ ΡΡΠ°Π²ΠΌΡ. ΠΠ° Π²ΡΠΎΡΠΎΠΌ ΡΡΠ°ΠΏΠ΅ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ ΠΏΠΎΠΈΡΠΊ ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΡΠΈΠ±ΠΎΠ² Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° ΠΏΠΎ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡΠΌ, ΠΎΠ±ΠΎΠ·Π½Π°ΡΠ΅Π½Π½ΡΠΌ Π½Π° ΠΏΠ΅ΡΠ²ΠΎΠΌ ΡΡΠ°ΠΏΠ΅. ΠΡΠΈΡΠ΅ΡΠΈΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½Ρ ΠΏΡΠΈ ΡΠΏΠ»ΠΎΡΠ½ΠΎΠΌ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΌ Π°Π½Π°Π»ΠΈΠ·Π΅ 726 ΡΠ»ΡΡΠ°Π΅Π², ΠΊΠΎΡΠΎΡΡΠ΅ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 6 Π³ΡΡΠΏΠΏ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: Π±ΡΠ»ΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ ΠΎΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΏΠΎ ΠΊΠ°ΠΆΠ΄ΠΎΠΌΡ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ»ΠΎΠΆΠ½ΡΡ
Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΉ, ΠΎΠ±ΠΎΠ·Π½Π°ΡΠ΅Π½Π½ΡΡ
Π½Π° ΠΏΠ΅ΡΠ²ΠΎΠΌ ΡΡΠ°ΠΏΠ΅ ΡΠ°Π±ΠΎΡΡ. ΠΡΠΈΠ·Π½Π°ΠΊΠΈ ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Ρ ΠΈΠ· ΡΠΈΡΠ»Π° Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΡΠΎΡΡΠΎ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΡ
ΡΠ΅ΡΡΠΎΠ². ΠΡΠ²ΠΎΠ΄: ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΈΠ½ΡΠΈΠΏ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² ΠΏΠΎ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡΠΌ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π§ΠΠ’, ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ» Π²ΡΠ΄Π΅Π»ΠΈΡΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Ρ Π² ΠΎΡΠ½ΠΎΠ²Ρ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΡΡΠ΅Π΄ΡΡΠ² ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠΈ ΠΏΡΠΈΠ½ΡΡΠΈΡ Π²ΡΠ°ΡΠ΅Π±Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ
Heavy-meson physics and flavour violation with a single generation
We study flavour-violating processes which involve heavy B- and D-mesons and
are mediated by Kaluza-Klein modes of gauge bosons in a previously suggested
model where three generations of the Standard Model fermions originate from a
single generation in six dimensions. We find the bound on the size R of the
extra spatial dimensions 1/R>3.3 TeV, which arises from the three-body decay
B_s to K mu e. Due to the still too low statistics this bound is much less
stringent than the constraint arising from K to mu e, 1/R>64 TeV, which was
found in a previous work (Frere et al., JHEP, 2003). Nevertheless, we argue
that a clear signature of the model would be an observation of K to mu e and
B_s to K mu e decays without observations of other flavour and lepton number
changing processes at the same precision level.Comment: 15 page
ΠΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠΏΠΎΠ½ΠΈΠ½Π° I ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΉ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ (ΠΏΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ AMIRI-CABG)
In 2017, the European Society of Cardiology outlined the importance of the problem of diagnosing myocardial ischemia-reperfusion injury following coronary artery bypass grafting. Myocardial injury can be accompanied by a critical decline in the cardiac index and an increase in cardiac troponin I plasma levels. The prognostic value troponin I elevation after coronary artery bypass grafting is poorly understood. Objective: to determine the prognostic value of troponin I plasma levels in relation to a fall in the cardiac index after coronary artery bypass grafting (CABG). Task: To determine the probability the cardiac index falling below 2.2 for troponin I levels in the first hours, and on days 1, 2, 3, 4 after CABG. Materials and methods. The single-center, non-randomized prospective study, running from 2016 to 2019, included 336 patients admitted for elective surgical treatment of coronary artery disease. The CABG patients were divided into three observation groups: off-pump (n = 175), on-pump (n = 128), and pump-assisted (n = 33). Troponin I levels were measured in the first hours, and on days 1, 2, 3, 4 after surgery using the Pathfast Compact immunoassay analyzer. Cardiac index was measured by invasive method. Results. In patients with a cardiac index higher than 2.2, troponin I level did not exceed 0.5 ng/mL in the off-pump group, 6 ng/mL in the on-pump group, and 3.5 ng/mL in the pump-assisted group. Patients with cardiac index lower than 2.2 have comparable troponin I levels in all groups - 21 ng/mL. Troponin I thresholds on day 1 after surgery, which, when exceeded, was associated with the likelihood of the cardiac index falling below 2.2, was 3.78 ng/mL in the off-pump group, 9.67 ng/mL in the on-pump group and 17.06 ng/mL in the pump-assisted group. Conclusion. After off-pump CABG, clinically significant myocardial injury should be expected at lower troponin I levels (3.78 ng/mL) than after on-pump CABG (9.67 ng/mL) and pump-assisted CABG (14.7 ng/mL).Π 2017 Π³ΠΎΠ΄Ρ ΠΠ²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΎΠ΅ ΠΎΠ±ΡΠ΅ΡΡΠ²ΠΎ ΠΊΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΎΠ² ΠΎΠ±ΠΎΠ·Π½Π°ΡΠΈΠ»ΠΎ Π²Π°ΠΆΠ½ΠΎΡΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈ-ΡΠ΅ΠΏΠ΅ΡΡΡΠ·ΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΉ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ. ΠΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΌΠΎΠΆΠ΅Ρ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°ΡΡΡΡ ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠΎΠΏΠΎΠ½ΠΈΠ½Π° I Π² ΠΊΡΠΎΠ²ΠΈ. ΠΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΡΠΎΠ²Π½Ρ ΡΡΠΎΠΏΠΎΠ½ΠΈΠ½Π° I ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΉ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΎ. Π¦Π΅Π»Ρ: ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΡΡΠΎΠΏΠΎΠ½ΠΈΠ½Π° I Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΉ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ. ΠΠ°Π΄Π°ΡΠΈ: ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΌΠ΅Π½Π΅Π΅ 2,2 Π΄Π»Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΉ ΡΡΠΎΠΏΠΎΠ½ΠΈΠ½Π° I Π² ΠΏΠ΅ΡΠ²ΡΠ΅ ΡΠ°ΡΡ, Π½Π° 1, 2, 3, 4-Π΅ ΡΡΡΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΉ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΎΠ΄Π½ΠΎΡΠ΅Π½ΡΡΠΎΠ²ΠΎΠ΅ Π½Π΅ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 336 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠΎΡΡΡΠΏΠΈΠ²ΡΠΈΡ
Π΄Π»Ρ ΠΏΠ»Π°Π½ΠΎΠ²ΠΎΠ³ΠΎ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΡΠ΅ΡΠ΄ΡΠ° Ρ 2016-Π³ΠΎ ΠΏΠΎ 2019 Π³. ΠΠ°ΡΠΈΠ΅Π½ΡΡ Π±ΡΠ»ΠΈ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ Π² ΡΡΠΈ Π³ΡΡΠΏΠΏΡ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ: ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ΅ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π±Π΅Π· ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ (n = 175), Ρ ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΡΠΌ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠ΅ΠΌ (n = 128) ΠΈ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΏΠ°ΡΠ°Π»Π»Π΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ (n = 33). ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΡΡΠΎΠΏΠΎΠ½ΠΈΠ½Π° I ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Π² ΠΏΠ΅ΡΠ²ΡΠ΅ ΡΠ°ΡΡ, Π½Π° 1, 2, 3, 4-Π΅ ΡΡΡΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΡΠΈΠ±ΠΎΡΠ° Pathfast Compact immuno-analyzer. Π‘Π΅ΡΠ΄Π΅ΡΠ½ΡΠΉ ΠΈΠ½Π΄Π΅ΠΊΡ ΠΈΠ·ΠΌΠ΅ΡΡΠ»ΠΈ ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΡΠΌ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠΌ Π±ΠΎΠ»Π΅Π΅ 2,2 ΡΡΠΎΠ²Π΅Π½Ρ ΡΡΠΎΠΏΠΎΠ½ΠΈΠ½Π° I Π² Π³ΡΡΠΏΠΏΠ΅ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π±Π΅Π· ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ Π½Π΅ ΠΏΡΠ΅Π²ΡΡΠ°Π» 0,5 Π½Π³/ΠΌΠ», Π² Π³ΡΡΠΏΠΏΠ΅ Ρ ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΡΠΌ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠ΅ΠΌ - 6 Π½Π³/ΠΌΠ», Π² Π³ΡΡΠΏΠΏΠ΅ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π½Π° ΠΏΠ°ΡΠ°Π»Π»Π΅Π»ΡΠ½ΠΎΠΌ ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎΠΌ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠΈ - 3,5 Π½Π³/ΠΌΠ». ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΡΡΠΎΠΏΠΎΠ½ΠΈΠ½Π° I Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΡΠΌ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠΌ 2,2 ΠΈ ΠΌΠ΅Π½Π΅Π΅ Π±ΡΠ»Π° ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΠ° Π² Π³ΡΡΠΏΠΏΠ°Ρ
Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 21 Π½Π³/ΠΌΠ». ΠΠΎΡΠΎΠ³ΠΎΠ²Π°Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΡΡΠΎΠΏΠΎΠ½ΠΈΠ½Π° I Π½Π° 1-ΠΉ Π΄Π΅Π½Ρ ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ, ΠΏΡΠ΅Π²ΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΡΠΎΠΉ Π±ΡΠ»ΠΎ ΡΠ²ΡΠ·Π°Π½ΠΎ Ρ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡΡ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΌΠ΅Π½Π΅Π΅ 2,2, ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 3,78; 9,67 ΠΈ 17,06 Π½Π³/ΠΌΠ» Π² Π³ΡΡΠΏΠΏΠ°Ρ
Π±Π΅Π· ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ, Ρ ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΡΠΌ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΈ Π½Π° ΠΏΠ°ΡΠ°Π»Π»Π΅Π»ΡΠ½ΠΎΠΌ ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎΠΌ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠΈ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΉ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π±Π΅Π· ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΡΠ»Π΅Π΄ΡΠ΅Ρ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°ΡΡ ΠΏΡΠΈ Π±ΠΎΠ»Π΅Π΅ Π½ΠΈΠ·ΠΊΠΈΡ
ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡΡ
ΡΡΠΎΠΏΠΎΠ½ΠΈΠ½Π° I (3,78 Π½Π³/ΠΌΠ»), ΡΠ΅ΠΌ ΠΏΠΎΡΠ»Π΅ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Ρ ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΡΠΌ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠ΅ΠΌ (9,67 Π½Π³/ΠΌΠ») ΠΈ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΏΠ°ΡΠ°Π»Π»Π΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ (14,7 Π½Π³/ΠΌΠ»)
Development and validation of an ultra?performance liquid chromatography quadrupole time of flight mass spectrometry method for rapid quantification of free amino acids in human urine
An ultra-performance liquid chromatography quadrupole time of flight mass spectrometry (UPLC-qTOFMS)method using hydrophilic interaction liquid chromatography was developed and validated for simultaneous quantification of 18 free amino acids in urine with a total acquisition time including the column re-equilibration of less than 18 min per sample. This method involves simple sample preparation steps which consisted of 15 times dilution with acetonitrile to give a final composition of 25 % aqueous and 75 % acetonitrile without the need of any derivatization. The dynamic range for our calibration curve is approximately two orders of magnitude (120-fold from the lowest calibration curve point) with good linearity (r2 ? 0.995 for all amino acids). Good separation of all amino acids as well as good intra- and inter-day accuracy (<15 %) and precision (<15 %) were observed using three quality control samples at a concentration of low, medium and high range of the calibration curve. The limits of detection (LOD) and lower limit of quantification of our method were ranging from approximately 1β300 nM and 0.01β0.5 Β΅M, respectively. The stability of amino acids in the prepared urine samples was found to be stable for 72 h at 4 Β°C, after one freeze thaw cycle and for up to 4 weeks at ?80 Β°C. We have applied this method to quantify the content of 18 free amino acids in 646 urine samples from a dietary intervention study. We were able to quantify all 18 free amino acids in these urine samples, if they were present at a level above the LOD. We found our method to be reproducible (accuracy and precision were typically <10 % for QCL, QCM and QCH) and the relatively high sample throughput nature of this method potentially makes it a suitable alternative for the analysis of urine samples in clinical setting
Organization of providing service to epileptologlcal patients in Tyumen city and in the South of Tyumen region
Opening of Epiieptologicai Center and interterritorial epileptological rooms will improve the quality and availability of epileptological service to the population of Tyumen and South of the Tyumen region.ΠΡΠΊΡΡΡΠΈΠ΅ ΡΠΏΠΈΠ»Π΅ΠΏΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅Π½ΡΡΠ° ΠΈ ΠΌΠ΅ΠΆΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΠΏΠΈΠ»Π΅ΠΏΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΠ°Π±ΠΈΠ½Π΅ΡΠΎΠ² ΡΠ»ΡΡΡΠΈΡ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΈ Π΄ΠΎΡΡΡΠΏΠ½ΠΎΡΡΡ ΠΎΠΊΠ°Π·Π°Π½ΠΈΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΏΠΈΠ»Π΅ΠΏΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π³.Π’ΡΠΌΠ΅Π½ΠΈ ΠΈ ΡΠ³Π° Π’ΡΠΌΠ΅Π½ΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ
ΠΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΡΠ΅ΡΠ΄ΡΠ° β Π°ΠΎΡΡΠΎΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ΅ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅, ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ Π°ΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΡΡ ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠΎΠ² ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°: ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ, ΡΠ»Π΅ΠΏΠΎΠ³ΠΎ, ΠΏΠ»Π°ΡΠ΅Π±ΠΎ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΠ΅ΠΌΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
Introduction. Despite resounding success in treatment of patients with coronary heart disease (CHD), researchers are yet unable to significantly reduce mortality in this disease. With this in mind, there are ongoing studies everywhere, which are aimed at investigating new techniques in order to boost the efficiency of existing standards. One of such promising techniques is cell/regenerative therapy with autologous bone marrow mononuclear cells (ABMMCs). However, even though ABMMCs have been studied for more than 10 years, there are no unambiguous data yet on several issues. Objective: to evaluate the outcome of ABMMC transplantation during coronary artery bypass grafting (CABG) surgery in combined treatment of CHD. Materials and methods. The data of 408 patients admitted to the clinic from 2013 to 2016 for planned surgical treatment of CHD were analyzed. The work included 117 people based on the design of the study. Patients were randomized in 3 groups: Group 0 (control group) β CABG surgery and intramyocardial injection of 0.9% NaCl solution, Group 1 β CABG surgery and intramyocardial injection of ABMMCs, Group 2 β CABG surgery, intramyocardial and intra-graft injection of ABMMCs. The dynamics was assessed 12 months later β functional class of angina pectoris and heart failure, echocardiography, speckle tracking (assessment of the degree of myocardial deformation), treadmill test, 6-minute walk test, daily ECG monitoring, quality of life questionnaires, coronary angiography. Qualitative indicators were calculated using the Pearsonβs chi-squared test and Fisher criteria. Quantitative indicators were calculated using the KruskalβWallis and Wilcoxon tests. Factor analysis was used to identify certain severity factors and to study data homogeneity. Discriminant analysis was performed to investigate the leading characteristics that determine differentiation between the groups. For analysis of variance, taking into account various factors, the model of variance analysis for dependent samples β Repeated Measures ANOVA β was used. Results. In the observation groups, an improvement in both systolic and diastolic myocardial function was universally noted. A six-minute walk test showed statistically significant increase in Groups 1 and 2 compared with the control Group 0 β 315.06 Β± 17.6 (433.54 Β± 20.6), Group 1 β 319.8 Β± 24.5 (524.4 Β± 28.7), Group 2 β 329.9 Β± 25.3 (452.7 Β± 29.7) meters. A significant decrease in the functional class of exertional angina pectoris in Groups 1 and 2 was noted unlike in the control group. The percentage of functioning coronary shunts after a 12-month follow-up period was 87.6% in Group 0. In Groups 1 and 2, this ratio was 96.2% and 97.3%, respectively. Predictors of overall effectiveness were identified: smoking, initial diastolic myocardial dysfunction, left ventricular ejection fraction. Conclusion. In addition to surgical treatment of coronary heart disease, ABMMC transplantation can improve myocardial contractility, boost exercise tolerance, and increase the duration of the functioning of coronary shunts at the follow-up period of 12 months. The study showed the need for stage-by-stage analytical calculations with the aim of possible correction of further work.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ΅ΡΠΌΠΎΡΡΡ Π½Π° Π½Π΅ΡΠΎΠΌΠ½Π΅Π½Π½ΡΠ΅ ΡΡΠΏΠ΅Ρ
ΠΈ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ ΡΠ΅ΡΠ΄ΡΠ° (ΠΠΠ‘), ΠΏΠΎΠΊΠ° Π½Π΅ ΡΠ΄Π°Π΅ΡΡΡ Π΄ΠΎΠ±ΠΈΡΡΡΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈ Π΄Π°Π½Π½ΠΎΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΈ. Π£ΡΠΈΡΡΠ²Π°Ρ ΡΡΠΎ, Π² Π½Π°ΡΡΠΎΡΡΠΈΠΉ ΠΌΠΎΠΌΠ΅Π½Ρ ΠΏΠΎΠ²ΡΠ΅ΠΌΠ΅ΡΡΠ½ΠΎ Π²Π΅Π΄ΡΡΡΡ ΡΠ°Π±ΠΎΡΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π½ΠΎΠ²ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊ Ρ ΡΠ΅Π»ΡΡ ΡΠ²Π΅Π»ΠΈΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠΆΠ΅ ΡΡΡΠ΅ΡΡΠ²ΡΡΡΠΈΡ
ΡΡΠ°Π½Π΄Π°ΡΡΠΎΠ². ΠΠ΄Π½ΠΎΠΉ ΠΈΠ· ΡΠ°ΠΊΠΈΡ
ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΊΠ»Π΅ΡΠΎΡΠ½Π°Ρ/ΡΠ΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠ²Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π°ΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΡΠΌΠΈ ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ°ΠΌΠΈ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° (ΠΠΠΠΠ). ΠΠ΄Π½Π°ΠΊΠΎ Π½Π΅ΡΠΌΠΎΡΡΡ Π½Π° ΡΠΎ ΡΡΠΎ ΠΠΠΠΠ ΠΈΡΡΠ»Π΅Π΄ΡΡΡΡΡ Π½Π° ΠΏΡΠΎΡΡΠΆΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»Π΅Π΅ 10 Π»Π΅Ρ, ΠΊ Π½Π°ΡΡΠΎΡΡΠ΅ΠΌΡ ΠΌΠΎΠΌΠ΅Π½ΡΡ Π½Π΅ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΎ ΠΎΠ΄Π½ΠΎΠ·Π½Π°ΡΠ½ΡΡ
Π΄Π°Π½Π½ΡΡ
ΠΏΠΎ ΡΡΠ΄Ρ Π²ΠΎΠΏΡΠΎΡΠΎΠ². Π¦Π΅Π»Ρ. ΠΡΠΎΠ²Π΅ΡΡΠΈ ΠΎΡΠ΅Π½ΠΊΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΠΠΠΠ ΠΏΡΠΈ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ Π°ΠΎΡΡΠΎΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ (ΠΠΠ¨) Π² ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΠΠ‘. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½Ρ Π΄Π°Π½Π½ΡΠ΅ 408 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠΎΡΡΡΠΏΠΈΠ²ΡΠΈΡ
Π² ΠΊΠ»ΠΈΠ½ΠΈΠΊΡ Ρ 2013-Π³ΠΎ ΠΏΠΎ 2016 Π³. Π΄Π»Ρ ΠΏΠ»Π°Π½ΠΎΠ²ΠΎΠ³ΠΎ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΠΠ‘. Π ΡΠ°Π±ΠΎΡΡ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 117 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ ΡΠΎΠ³Π»Π°ΡΠ½ΠΎ Π΄ΠΈΠ·Π°ΠΉΠ½Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·Π°ΡΠΈΡ Π² 3 Π³ΡΡΠΏΠΏΡ: Π³ΡΡΠΏΠΏΠ° 0 β ΠΎΠΏΠ΅ΡΠ°ΡΠΈΡ ΠΠΠ¨ ΠΈ ΠΈΠ½ΡΡΠ°ΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΠΎΠ΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ 0,9% ΡΠ°ΡΡΠ²ΠΎΡΠ° NaCl β ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ Π³ΡΡΠΏΠΏΠ°, Π³ΡΡΠΏΠΏΠ° 1 β ΠΎΠΏΠ΅ΡΠ°ΡΠΈΡ ΠΠΠ¨ ΠΈ ΠΈΠ½ΡΡΠ°ΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΠΎΠ΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΠΠΠΠ, Π³ΡΡΠΏΠΏΠ° 2 β ΠΎΠΏΠ΅ΡΠ°ΡΠΈΡ ΠΠΠ¨, ΠΈΠ½ΡΡΠ°ΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΠΎΠ΅ ΠΈ Π²Π½ΡΡΡΠΈΡΡΠ½ΡΠΎΠ²ΠΎΠ΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΠΠΠΠ. Π§Π΅ΡΠ΅Π· 12 ΠΌΠ΅ΡΡΡΠ΅Π² Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΠΎΡΠ΅Π½ΠΊΠ° Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ β ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ»Π°ΡΡΠ° ΡΡΠ΅Π½ΠΎΠΊΠ°ΡΠ΄ΠΈΠΈ Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΡ ΠΈ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ, ΠΡ
ΠΎΠΠ, speckle tracking (ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π΄Π΅ΡΠΎΡΠΌΠ°ΡΠΈΠΈ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°), ΡΡΠ΅Π΄ΠΌΠΈΠ»-ΡΠ΅ΡΡΠ°, ΡΠ΅ΡΡΠ° Ρ 6-ΠΌΠΈΠ½ΡΡΠ½ΠΎΠΉ Ρ
ΠΎΠ΄ΡΠ±ΠΎΠΉ, ΡΡΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΠΠ, ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊΠΎΠ² ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ, ΠΊΠΎΡΠΎΠ½Π°ΡΠΎΠ³ΡΠ°ΡΠΈΠΈ. ΠΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠ°ΡΡΡΠΈΡΠ°Π½Ρ ΠΏΡΠΈ ΠΏΠΎΠΌΠΎΡΠΈ ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² ΠΠΈΡΡΠΎΠ½Π° (Ο2 ) ΠΈ Π€ΠΈΡΠ΅ΡΠ°. ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ β ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ ΠΡΠ°ΡΠΊΠ΅Π»Π°βΠ£ΠΎΠ»Π»ΠΈΡΠ° ΠΈ ΠΠΈΠ»ΠΊΠΎΠΊΡΠΎΠ½Π°. ΠΠ»Ρ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΡΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΡΠΆΠ΅ΡΡΠΈ ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΠ΄Π½ΠΎΡΠΎΠ΄Π½ΠΎΡΡΠΈ Π΄Π°Π½Π½ΡΡ
β ΡΠ°ΠΊΡΠΎΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ·. ΠΠ»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π²Π΅Π΄ΡΡΠΈΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ, ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡΠΈΡ
Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΡ ΠΌΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ, ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ Π΄ΠΈΡΠΊΡΠΈΠΌΠΈΠ½Π°Π½ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ·. ΠΠ»Ρ Π°Π½Π°Π»ΠΈΠ·Π° Π΄ΠΈΡΠΏΠ΅ΡΡΠΈΠΈ Ρ ΡΡΠ΅ΡΠΎΠΌ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΌΠΎΠ΄Π΅Π»Ρ Π΄ΠΈΡΠΏΠ΅ΡΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π΄Π»Ρ Π·Π°Π²ΠΈΡΠΈΠΌΡΡ
Π²ΡΠ±ΠΎΡΠΎΠΊ β Repeated Measures ANOVA. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Π³ΡΡΠΏΠΏΠ°Ρ
Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΠΏΠΎΠ²ΡΠ΅ΠΌΠ΅ΡΡΠ½ΠΎ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠ°ΠΊ ΡΠΈΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ, ΡΠ°ΠΊ ΠΈ Π΄ΠΈΠ°ΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°. Π’Π΅ΡΡ Ρ 6-ΠΌΠΈΠ½ΡΡΠ½ΠΎΠΉ Ρ
ΠΎΠ΄ΡΠ±ΠΎΠΉ ΠΏΠΎΠΊΠ°Π·Π°Π» ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠΉ ΠΏΡΠΈΡΠΎΡΡ Π² Π³ΡΡΠΏΠΏΠ°Ρ
1 ΠΈ 2 ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ: Π³ΡΡΠΏΠΏΠ° 0 β 315,06 Β± 17,6 (433,54 Β± 20,6), Π³ΡΡΠΏΠΏΠ° 1 β 319,8 Β± 24,5 (524,4 Β± 28,7), Π³ΡΡΠΏΠΏΠ° 2 β 329,9 Β± 25,3 (452,7 Β± 29,7) ΠΌΠ΅ΡΡΠ°. ΠΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ»Π°ΡΡΠ° ΡΡΠ΅Π½ΠΎΠΊΠ°ΡΠ΄ΠΈΠΈ Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΡ Π² Π³ΡΡΠΏΠΏΠ°Ρ
1 ΠΈ 2 ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠΎΠΉ. ΠΡΠΎΡΠ΅Π½Ρ ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΡΡΡΠΈΡ
ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΡ
ΡΡΠ½ΡΠΎΠ² ΡΠ΅ΡΠ΅Π· 12 ΠΌΠ΅ΡΡΡΠ΅Π² Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ» 87,6% Π² Π³ΡΡΠΏΠΏΠ΅ 0, Π² Π³ΡΡΠΏΠΏΠ°Ρ
1 ΠΈ 2 ΡΡΠΎ ΡΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΎ 96,2% ΠΈ 97,3% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΡΡΠ²Π»Π΅Π½Ρ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΡ ΠΎΠ±ΡΠ΅ΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ: ΠΊΡΡΠ΅Π½ΠΈΠ΅, ΠΈΡΡ
ΠΎΠ΄Π½Π°Ρ Π΄ΠΈΠ°ΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠ°Ρ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΡ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°, ΡΡΠ°ΠΊΡΠΈΡ Π²ΡΠ±ΡΠΎΡΠ° Π»Π΅Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠ°. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π’ΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ ΠΠΠΠΠ Π² Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ ΠΊ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌΡ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΠΠ‘ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ»ΡΡΡΠΈΡΡ ΡΠΎΠΊΡΠ°ΡΠΈΡΠ΅Π»ΡΠ½ΡΡ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°, ΡΠ²Π΅Π»ΠΈΡΠΈΡΡ ΡΠΎΠ»Π΅ΡΠ°Π½ΡΠ½ΠΎΡΡΡ ΠΊ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π½Π°Π³ΡΡΠ·ΠΊΠ°ΠΌ, ΡΠ²Π΅Π»ΠΈΡΠΈΡΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΡ
ΡΡΠ½ΡΠΎΠ² Π² ΡΡΠΎΠΊΒ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ 12 ΠΌΠ΅ΡΡΡΠ΅Π². ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΡΠ°ΠΏΠ½ΡΡ
Π°Π½Π°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΡΡΠ΅ΡΠΎΠ² Ρ ΡΠ΅Π»ΡΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠΉ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π³ΠΎ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΡ ΡΠ°Π±ΠΎΡΡ
Metabolic Linkage and Correlations to Storage Capacity in Erythrocytes from Glucose 6-Phosphate Dehydrogenase-Deficient Donors
ObjectiveIn glucose 6-phosphate dehydrogenase (G6PD) deficiency, decreased NADPH regeneration in the pentose phosphate pathway and subnormal levels of reduced glutathione result in insufficient antioxidant defense, increased susceptibility of red blood cells (RBCs) to oxidative stress, and acute hemolysis following exposure to pro-oxidant drugs and infections. Despite the fact that redox disequilibrium is a prominent feature of RBC storage lesion, it has been reported that the G6PD-deficient RBCs store well, at least in respect to energy metabolism, but their overall metabolic phenotypes and molecular linkages to the storability profile are scarcely investigated.MethodsWe performed UHPLC-MS metabolomics analyses of weekly sampled RBC concentrates from G6PD sufficient and deficient donors, stored in citrate phosphate dextrose/saline adenine glucose mannitol from day 0 to storage day 42, followed by statistical and bioinformatics integration of the data.ResultsOther than previously reported alterations in glycolysis, metabolomics analyses revealed bioactive lipids, free fatty acids, bile acids, amino acids, and purines as top variables discriminating RBC concentrates for G6PD-deficient donors. Two-way ANOVA showed significant changes in the storage-dependent variation in fumarate, one-carbon, and sulfur metabolism, glutathione homeostasis, and antioxidant defense (including urate) components in G6PD-deficient vs. sufficient donors. The levels of free fatty acids and their oxidized derivatives, as well as those of membrane-associated plasticizers were significantly lower in G6PD-deficient units in comparison to controls. By using the strongest correlations between in vivo and ex vivo metabolic and physiological parameters, consecutively present throughout the storage period, several interactomes were produced that revealed an interesting interplay between redox, energy, and hemolysis variables, which may be further associated with donor-specific differences in the post-transfusion performance of G6PD-deficient RBCs.ConclusionThe metabolic phenotypes of G6PD-deficient donors recapitulate the basic storage lesion profile that leads to loss of metabolic linkage and rewiring. Donor-related issues affect the storability of RBCs even in the narrow context of this donor subgroup in a way likely relevant to transfusion medicine
Assessment of safety of additional transplantation of autologous bone marrow mononuclear cells in the combined treatment of coronary heart disease. Results from a randomized, blind, placebo-controlled trial (TAMIS)
Aim: to assess the safety of transplantation of autologous bone marrow mononuclear cells when performing coronary artery bypass grafting in the combined treatment of ischemic heart disease in patients with coronary and heart failure.Materials and methods. During the period from 2013 to 2016 years 117 patients, who meet the established criteria, were included in the work. Randomization was performed in observation groups: group 0 -control group (coronary artery bypass grafting (CABG) and intramyocardial administration of a 0.9% NaCl solution), group 1 - CABG surgery and intramyocardial administration of autologous bone marrow mononuclear cells (ABMMS), group 2 - CABG surgery and intramyocardial and intragraft administration of ABMMS. Clinical, laboratory - CPK MB, myoglobin, troponin I, HCT, Hb, K +, ABC; instrumental (stress tests, echocardiography, speckle tracking, coronary angiography) data were evaluated in these groups. The analysis of the frequency of postoperative complications (hydrothorax, hydropericardium, rhythm disturbances) was performed; the length of stay in the intensive care unit, the length of stay in the hospital and other indicators. After 6 and 12 months, the overall mortality was assessed, major cardiac events - the development of acute myocardial infarction, ventricular arrhythmias, oncological alertness. Number in international register clinical trials Clinical Trial. gov Identifier: NCT02059512.Results. Statistical analysis showed no statistically significant differences in the observation groups for the compared criteria.Conclusion. Transplantation of autologous bone marrow mononuclear cells during aorto-coronary bypass surgery in the combined treatment of coronary heart disease is a safe method